«NCI Drug Dictionary». National Cancer Institute. 2 Φεβρουαρίου 2011. Αρχειοθετήθηκε από το πρωτότυπο στις 25 Απριλίου 2015. Ανακτήθηκε στις 20 Δεκεμβρίου 2016.
«Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment». American Journal of Hematology89 (12): 1132–40. December 2014. doi:10.1002/ajh.23828. PMID25407896.
«The evolution of T-cell depletion in haploidentical stem-cell transplantation». British Journal of Haematology172 (5): 667–84. March 2016. doi:10.1111/bjh.13868. PMID26684279.
«Lung toxicity associated with cyclophosphamide use. Two distinct patterns». American Journal of Respiratory and Critical Care Medicine154 (6 Pt 1): 1851–6. December 1996. doi:10.1164/ajrccm.154.6.8970380. PMID8970380.
«Water intoxication following moderate-dose intravenous cyclophosphamide». Archives of Internal Medicine145 (3): 548–9. March 1985. doi:10.1001/archinte.145.3.548. PMID3977522.
«Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus». Lupus12 (8): 636–9. 2003. doi:10.1191/0961203303lu421cr. PMID12945725.
«Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review». Arthritis and Rheumatism62 (1): 9–21. January 2010. doi:10.1002/art.25061. PMID20039416.
«Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus». Arthritis and Rheumatism39 (9): 1475–82. September 1996. doi:10.1002/art.1780390906. PMID8814058.
«When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases». Arthritis and Rheumatism59 (7): 1034–9. July 2008. doi:10.1002/art.23822. PMID18576286.
«Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis». European Journal of Clinical Investigation45 (3): 346–68. March 2015. doi:10.1111/eci.12410. PMID25627555.
«Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis». Archives of Internal Medicine168 (4): 378–81. February 2008. doi:10.1001/archinternmed.2007.107. PMID18299492.
«Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study». Arthritis and Rheumatism38 (8): 1120–7. August 1995. doi:10.1002/art.1780380815. PMID7639809.
«Etiology and management of therapy-related myeloid leukemia». Hematology. American Society of Hematology. Education Program2007: 453–9. 2007. doi:10.1182/asheducation-2007.1.453. PMID18024664.
«Prodrugs--from serendipity to rational design». Pharmacological Reviews63 (3): 750–71. September 2011. doi:10.1124/pr.110.003459. PMID21737530.
Giraud, B (2010), «Oxazaphosphorines: new therapeutic strategies for an old class of drugs», Expert Opin Drug Metab Toxicol6 (8): 919–938, doi:10.1517/17425255.2010.487861, PMID20446865
«Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies». Blood Reviews6 (3): 163–73. September 1992. doi:10.1016/0268-960X(92)90028-O. PMID1422285.
«Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines». Biochemical Pharmacology34 (19): 3465–71. October 1985. doi:10.1016/0006-2952(85)90719-1. PMID2996550.
«Immunomodulatory effects of cyclophosphamide and implementations for vaccine design». Seminars in Immunopathology33 (4): 369–83. July 2011. doi:10.1007/s00281-011-0245-0. PMID21611872.
drugs.com
«Cyclophosphamide». The American Society of Health-System Pharmacists. Αρχειοθετήθηκε από το πρωτότυπο στις 2 Ιανουαρίου 2017. Ανακτήθηκε στις 8 Δεκεμβρίου 2016.
«Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment». American Journal of Hematology89 (12): 1132–40. December 2014. doi:10.1002/ajh.23828. PMID25407896.
«The evolution of T-cell depletion in haploidentical stem-cell transplantation». British Journal of Haematology172 (5): 667–84. March 2016. doi:10.1111/bjh.13868. PMID26684279.
«Lung toxicity associated with cyclophosphamide use. Two distinct patterns». American Journal of Respiratory and Critical Care Medicine154 (6 Pt 1): 1851–6. December 1996. doi:10.1164/ajrccm.154.6.8970380. PMID8970380.
«Water intoxication following moderate-dose intravenous cyclophosphamide». Archives of Internal Medicine145 (3): 548–9. March 1985. doi:10.1001/archinte.145.3.548. PMID3977522.
«Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus». Lupus12 (8): 636–9. 2003. doi:10.1191/0961203303lu421cr. PMID12945725.
«Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review». Arthritis and Rheumatism62 (1): 9–21. January 2010. doi:10.1002/art.25061. PMID20039416.
«Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus». Arthritis and Rheumatism39 (9): 1475–82. September 1996. doi:10.1002/art.1780390906. PMID8814058.
«When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases». Arthritis and Rheumatism59 (7): 1034–9. July 2008. doi:10.1002/art.23822. PMID18576286.
«Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis». European Journal of Clinical Investigation45 (3): 346–68. March 2015. doi:10.1111/eci.12410. PMID25627555.
«Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis». Archives of Internal Medicine168 (4): 378–81. February 2008. doi:10.1001/archinternmed.2007.107. PMID18299492.
«Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study». Arthritis and Rheumatism38 (8): 1120–7. August 1995. doi:10.1002/art.1780380815. PMID7639809.
«Etiology and management of therapy-related myeloid leukemia». Hematology. American Society of Hematology. Education Program2007: 453–9. 2007. doi:10.1182/asheducation-2007.1.453. PMID18024664.
Giraud, B (2010), «Oxazaphosphorines: new therapeutic strategies for an old class of drugs», Expert Opin Drug Metab Toxicol6 (8): 919–938, doi:10.1517/17425255.2010.487861, PMID20446865
«Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies». Blood Reviews6 (3): 163–73. September 1992. doi:10.1016/0268-960X(92)90028-O. PMID1422285.
«Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines». Biochemical Pharmacology34 (19): 3465–71. October 1985. doi:10.1016/0006-2952(85)90719-1. PMID2996550.
«Immunomodulatory effects of cyclophosphamide and implementations for vaccine design». Seminars in Immunopathology33 (4): 369–83. July 2011. doi:10.1007/s00281-011-0245-0. PMID21611872.
«NCI Drug Dictionary». National Cancer Institute. 2 Φεβρουαρίου 2011. Αρχειοθετήθηκε από το πρωτότυπο στις 25 Απριλίου 2015. Ανακτήθηκε στις 20 Δεκεμβρίου 2016.
«Cyclophosphamide». The American Society of Health-System Pharmacists. Αρχειοθετήθηκε από το πρωτότυπο στις 2 Ιανουαρίου 2017. Ανακτήθηκε στις 8 Δεκεμβρίου 2016.